Print Page     Close Window     

SEC Filings

10-K
BIOTIME INC filed this Form 10-K on 03/16/2017
Entire Document
 

PART II

Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities

Our common shares are traded on the NYSE MKT and on the TASE under the ticker symbol BTX. The following table sets forth the range of high and low closing prices for our common shares for the fiscal years ended December 31, 2015 and 2016, as reported by the NYSE MKT:

Quarter Ended
 
High
   
Low
 
March 31, 2015
 
$
5.46
   
$
3.81
 
June 30, 2015
 
$
5.88
   
$
3.51
 
September 30, 2015
 
$
3.71
   
$
2.53
 
December 31, 2015
 
$
4.38
   
$
3.19
 
March 31, 2016
 
$
3.68
   
$
2.08
 
June 30, 2016
 
$
3.25
   
$
2.29
 
September 30, 2016
 
$
3.97
   
$
2.70
 
December 31, 2016
 
$
3.89
   
$
2.89
 

As of February 28, 2017, there were 15,377 holders of the common shares based on the share position listing.

The following table shows certain information concerning the options outstanding and available for issuance under all of our compensation plans and agreements as of December 31, 2016 (in thousands, except weighted average exercise prices):

Plan Category
Number of
Shares to be
Issued upon
Exercise of
Outstanding
Options and
Vesting of Restricted
Stock Units, and
Rights
 
Weighted
Average
Exercise
Price of the
Outstanding
Options,
and
Rights
 
Number of
Shares
Remaining
Available for
Future Issuance
under Equity
Compensation
Plans
 
BioTime Equity Compensation Plans Approved by Shareholders(1)
   
7,058
(1) 
 
$
3.60
     
2,894
 

(1)
Includes 100,000 outstanding Restricted Stock Units, or RSUs.

The following table shows certain information concerning the options outstanding and available for issuance under all of the compensation plans and agreements for our consolidated subsidiary companies as of December 31, 2016 (in thousands, except weighted average exercise price per share):

   
Number of
Shares to be
Issued upon
Exercise of
Outstanding
Options
and
Rights
   
Weighted
Average Exercise
Price of the
Outstanding
Options,
and
Rights
   
Number of
Shares
Remaining
Available for
Future Issuance
under Equity
Compensation
Plans
 
OrthoCyte Equity Compensation Plans Approved by Shareholders(1)
   
1,300
   
$
0.06
     
2,700
 
OncoCyte Equity Compensation Plans Approved by Shareholders(1)
   
3,017
   
$
2.52
     
880
 
ReCyte Therapeutics Equity Compensation Plans Approved by Shareholders(1)
   
1,250
   
$
2.05
     
2,750
 
BioTime Asia Equity Compensation Plans Approved by Shareholders(1)
   
300
   
$
0.01
     
1,300
 
Cell Cure Compensation Plans Approved by Shareholders(1)(2)
   
81
   
$
38.00
     
44
 
LifeMap Sciences Equity Compensation Plans Approved by Shareholders(1)
   
1,596
   
$
1.44
     
746
 
LifeMap Solutions Compensation Plans Approved by Shareholders(1)
   
12
   
$
500.00
     
7
 

(1)
BioTime is, directly or through one or more subsidiaries, the majority shareholder. Except for OncoCyte, all other common stock underlying the stock options under the respective equity plans are privately-held.
(2)
Cell Cure Share Option Plan US dollar exercise price is approximated based on the conversion rate between the US dollar and the New Israeli Shekel, NIS, at the time of grant. The exercise price is denominated in NIS and is 154 per share.
 
53

© Copyright BioTime, Inc.